Licensing Assertion - Molecular Diagnostics Technology - Major Multinational

BACKGROUND

This Upstream project involved an infringed medical device for a multinational pharmaceutical company.

Our Analysis

  • Upstream determined that there was potential with a portfolio that addressed the detection of gene mutations, a diagnostic tool essential in a large variety of disease screening needs.

  • The Upstream team acquired these IP rights under an arrangement in which the IP owner would receive a percentage of any revenues Upstream derived from the patents.

  • The Upstream team consisted of two technical experts, with commercial expertise (one in the U.S. and one in the U.K.), and a patent attorney.

  • The Upstream team discovered dozens of likely infringers (i.e. companies with products that used techniques covered in the patent claims).

  • Upstream discovered and confirmed approximately five new infringers.

Outcome

The Upstream team executed royalty bearing licenses with more than ten companies. Total revenues from this program exceeded $30 million.

IP Valuation and MonetizationMARK CHANDLERIP MONETIZATION, IP LICENSING